8 companies in Roche Venture Fund's investment portfolio.
Back to Roche Venture Fund profile“Investing in breakthrough healthcare innovations that can transform patient outcomes and advance personalized medicine.”
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Healthcare technology company that develops software to accelerate cancer research and improve patient care through real-world evidence.
Foundation Medicine, Inc. is an American company based in Boston, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.
Clinical-stage precision medicine company using computational approaches to develop protein motion-based therapies for cancer.
Roche Venture Fund has built a portfolio of 8 companies across 2 sectors, including Biotech, Digital Health.
The portfolio reflects investments across the IPO, Series B stages, showing Roche Venture Fund's approach to supporting companies at multiple points in their growth journey.
Roche Venture Fund has invested in 8+ companies across 2 different sectors.
Roche Venture Fund's portfolio spans Biotech, Digital Health. This diversification reflects the firm's broad investment thesis and sector expertise.
Roche Venture Fund invests across the IPO, Series B stages. Their portfolio includes companies at various points in their growth journey.